These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32168001)

  • 21. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis.
    Testi I; Pavesio C
    Ther Deliv; 2019 Oct; 10(10):621-625. PubMed ID: 31663454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results of fluocinolone acetonide intravitreal implant in Behçet intractable posterior uveitis.
    Oh EK; Lee EK; Yu HG
    Can J Ophthalmol; 2014 Jun; 49(3):273-8. PubMed ID: 24862774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
    Suhler EB; Thorne JE; Mittal M; Betts KA; Tari S; Camez A; Bao Y; Joshi A
    Ophthalmology; 2017 Dec; 124(12):1799-1807. PubMed ID: 28689898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brucellosis and uveitis.
    Karahocagil MK; Demirok A; Kiliç A; Cinal A; Caksen H; Yasar T
    Ann Ophthalmol (Skokie); 2008; 40(1):48-50. PubMed ID: 18556983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
    Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant.
    Ufret-Vincenty RL; Singh RP; Lowder CY; Kaiser PK
    Am J Ophthalmol; 2007 Feb; 143(2):334-5. PubMed ID: 17258523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NONINFECTIOUS POSTERIOR UVEITIS: BRINGING EMERGING TREATMENTS TO THE FOREFRONT.
    Retina; 2020 Mar; 40 Suppl 3():S1-S12. PubMed ID: 32108725
    [No Abstract]   [Full Text] [Related]  

  • 29. Fluocinolone acetonide for the treatment of uveitis: weighing the balance between local and systemic immunosuppression.
    Yeh S; Nussenblatt RB
    Arch Ophthalmol; 2008 Sep; 126(9):1287-9. PubMed ID: 18779492
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.
    Pavesio C; Zierhut M; Bairi K; Comstock TL; Usner DW;
    Ophthalmology; 2010 Mar; 117(3):567-75, 575.e1. PubMed ID: 20079922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis].
    Couret C; Ducloyer JB; Touhami S; Angioi-Duprez K; Rougier MB; Labalette P; Titah C; Cochereau I; Kodjikian L; Mura F; Chiquet C; Weber M; Bodaghi B
    J Fr Ophtalmol; 2020 Apr; 43(4):341-361. PubMed ID: 31818505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug delivery options for the treatment of ocular inflammation.
    Lobo AM; Sobrin L; Papaliodis GN
    Semin Ophthalmol; 2010; 25(5-6):283-8. PubMed ID: 21091013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis.
    Chirikov VV; Shah R; Kwon Y; Patel D
    Ophthalmic Epidemiol; 2019 Feb; 26(1):27-46. PubMed ID: 30199301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
    Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
    Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MUST Beg to Differ.
    Albini T; Callaway NF; Jaffe GJ; Feuer W; Davis J; Goldstein D; Lowder C; Lin P; Nguyen Q; Srivastava S; Callanan D; Galor A; Goldhardt R; Flynn H
    Ophthalmic Surg Lasers Imaging Retina; 2019 May; 50(5):266-268. PubMed ID: 31100155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert).
    Patel CC; Mandava N; Oliver SC; Braverman R; Quiroz-Mercado H; Olson JL
    Retina; 2012 Mar; 32(3):537-42. PubMed ID: 21963487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).
    Nguyen QD; Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Thurau S; Abraham A; Wilson L; Yang Y; Shams N;
    Ophthalmology; 2016 Nov; 123(11):2413-2423. PubMed ID: 27692526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Think global--act local: intravitreal drug delivery systems in chronic noninfectious uveitis.
    Hazirolan D; Pleyer U
    Ophthalmic Res; 2013; 49(2):59-65. PubMed ID: 23258374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of Multiple Implants and Dissociation of Fluocinolone Acetonide Intravitreal Implant (Retisert) in a Series of 187 Consecutive Implants.
    Freitas-Neto CA; Maghsoudlou A; Dhanireddy S; Payal A; Boonsopon S; Ratwatte MD; Foster CS
    Ocul Immunol Inflamm; 2015; 23(6):425-9. PubMed ID: 25541739
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.